Co-Proxamol (Distalgesic) Procurement in Bahrain
نویسندگان
چکیده
منابع مشابه
Co-proxamol and suicide
Editor—We agree with Hawton et al that co-proxamol presents a major overdose hazard, their results illustrating the difficulties for licensing authorities in limiting availability of prescription medicines that are only hazardous in overdose. Co-proxamol is more likely to result in death; it causes prolongation of the QRS interval in an electrocardiogram in experimental animals and in humans. 3...
متن کاملHypersensitivity pneumonitis associated with co-proxamol (paracetamol + dextropropoxyphene) therapy.
A 61-year-old man developed hypersensitivity pneumonitis and skin rash in close association with taking co-proxamol. These problems occurred in spite of being treated with prednisolone 40 mg daily (20 mg daily at the time of presentation) for assumed cranial arteritis. A therapeutic challenge with paracetamol was negative and the patient continues to take this drug. It seems likely that this pa...
متن کاملCo-proxamol and suicide: preventing the continuing toll of overdose deaths.
Restricting means for suicide is a key element in suicide prevention strategies of all countries where these have been introduced. Preventing deaths from analgesic overdoses is highlighted in the National Suicide Prevention Strategy for England. The problem of self-poisoning with the prescription-only drug co-proxamol (dextropropoxyphene plus paracetamol) has received attention in several count...
متن کاملCo-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings.
OBJECTIVES To examine the incidence of suicides due to co-proxamol compared with tricyclic antidepressants and paracetamol, and to compare fatality rates for self poisonings with these drugs. DESIGN Analysis of routinely collected national and local data on suicides and self poisonings. SETTING Records of suicides in England and Wales 1997-9; non-fatal self poisonings in Oxford District 199...
متن کاملUse of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market
BACKGROUND Distalgesic, the prescription-only analgesic compound of paracetamol (325 mg) and dextropropoxyphene (32.5 mg) known as co-proxamol in the UK, was withdrawn from the Irish market as of January 2006. This study aimed to evaluate the impact of the withdrawal of distalgesic in terms of intentional drug overdose (IDO) presentations to hospital emergency departments (EDs) nationally. ME...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Principles and Practice
سال: 2009
ISSN: 1011-7571,1423-0151
DOI: 10.1159/000204361